Microdevice for Ovarian Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on anticoagulation medication (blood thinners), you may need to stop them unless you are only taking low-dose aspirin.
What data supports the effectiveness of this treatment for ovarian cancer?
The research shows that using a microdevice to deliver chemotherapy directly to ovarian cancer tumors in mice resulted in similar tumor reduction with less toxicity compared to traditional methods. Additionally, a microdevice used for drug sensitivity screening in ovarian cancer models accurately predicted treatment outcomes, suggesting potential effectiveness in guiding therapy decisions.12345
Is the implantable microdevice safe for use in humans?
Research on an implantable microdevice for delivering chemotherapy in ovarian cancer mouse models showed it caused less toxicity compared to traditional methods, suggesting it may be safer. Additionally, a study on a similar device in lung cancer patients found it safe for implantation and retrieval, indicating general safety in humans.12456
How is the Implantable Microdevice treatment for ovarian cancer different from other treatments?
The Implantable Microdevice treatment for ovarian cancer is unique because it uses a small device implanted in the body to test multiple cancer drugs simultaneously, allowing for personalized treatment plans. This approach is different from traditional treatments that typically involve systemic chemotherapy without such individualized testing.15678
What is the purpose of this trial?
This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer.The name of the study intervention involved in this study is:-implantable microdevice
Research Team
Elizabeth Stover, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for adults with advanced stage (III-IV) ovarian, fallopian tube, or peritoneal cancer. Candidates must be medically stable for procedures and willing to undergo genetic sequencing. They need a negative pregnancy test if of childbearing potential and cannot have uncontrolled illnesses or conditions that increase biopsy/surgery risks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Microdevice Placement and Evaluation
Participants undergo percutaneous placement of microdevices in tumor tissue, which dwell for approximately 24 +/- 8 hours to measure local intratumor response to drugs.
Surgical Procedure
Microdevices are removed by resection of the tumor mass during a planned surgical procedure.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including adverse events and progression-free survival.
Treatment Details
Interventions
- Implantable Microdevice
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Dana-Farber Cancer Institute
Collaborator
National Cancer Institute (NCI)
Collaborator